We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

EpiCypher™ Awards Five Epigenetic Research Grants

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

EpiCypher has announced the award of five grants for Histone Peptide Array Screening Services to researchers at Indiana University, Memorial Sloan Kettering Cancer Center, The University of Florida, The University of Montreal and The Structural Genomics Consortium as part of their first annual grant program in support of chromatin biology and epigenetics research.

The scientific founders of EpiCypher reviewed each grant application and selected the winners, each of whom will receive histone modification screening services employing EpiCypher’s world-class EpiTitan™ Histone Peptide Arrays, along with a statistical analysis of their protein’s or antibody’s histone modification binding profile.

The grantees are: Levi Blazer, Ph.D., Structural Genomics Consortium; El Bachir Affar, Ph.D., University of Montreal; Omar Abdel-Wahab, M.D., Memorial Sloan-Kettering Cancer Center; Feng-Chun Yang, Ph.D., Indiana University School of Medicine; and Daiqing Liao, Ph.D, University of Florida.

The grant recipients and their respective organizations will work individually but collaboratively with EpiCypher’s scientific team to help answer each project’s fundamental biological question.

EpiCypher is dedicated to giving researchers access to the highest quality, most productive approaches for more meaningful investigations into chromatin biology and epigenetics research.

“We look forward to introducing these winners to the many benefits of our transformative products and incorporating them into their research so they can experience their advantages to chromatin research first hand,” says EpiCypher CEO Sam Tetlow.